Unlock instant, AI-driven research and patent intelligence for your innovation.
Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A compound, technology for anxiety disorders, applied in the field of application of GAL3 receptor antagonists in the treatment of depression and/or anxiety and compounds useful therein, capable of solving problems such as reducing uncertainty or anxiety
Inactive Publication Date: 2009-04-15
H LUNDBECK AS
View PDF5 Cites 2 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Also, in these models, prior training reduces uncertainty or anxiety
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[2037] Example 1: N 2 -Cyclohexyl-N 2 -Methyl-N 4 -(4-methylphenyl)-6-(1-piperidinyl)-2,4-pyrimidinediamine : Prepared by Procedures D, G (for substitution with cyclohexylamine) and G. 1 H NMR (300MHz, CDCl 3 )δ7.22 (d, 2H, J=7.8), 7.12 (d, 2H, J=7.8), 5.29 (s, 1H), 4.43 (br s, 1H), 3.55-3.44 (m, 5H), 3.01 (s, 3H), 2.33 (s, 3H), 2.00-1.05 (m, 16H).
Embodiment 2
[2038] Example 2: N 2 -Cyclohexyl-N 2 -(2-Methoxyethyl)-N 4 -(4-methylphenyl)-6-(1-piperidinyl)-2,4- pyrimidinediamine : Prepared by procedures D, J (130° C.) and F (2 hours). 1 H NMR (300MHz, CDCl 3 )δ7.25 (d, 2H, J=8.1), 7.10 (d, 2H, J=8.1), 6.17 (br s, 1H), 5.31 (s, 1H), 4.58-4.43 (m, 1H), 3.61 -3.57(m, 4H), 3.52-3.48(m, 4H), 3.39(s, 3H), 2.31(s, 3H), 1.83-1.75(m, 4H), 1.70-1.50(m, 7H), 1.43 -1.37(m, 4H), 1.19-1.05(m, 1H); ESI-MS m / z 424(MH + ).
Embodiment 3
[2039] Example 3: N 4 -(4-Methylphenyl)-N 2 -Phenyl-6-(1-piperidinyl)-2,4-pyrimidinediamine : Via procedures A, B (substitution with aniline) and E (substitution with piperidine at 100° C.). 1 H NMR (300MHz, CDCl 3 )δ7.58(d, 2H, J=8.7), 7.26(t, 2H, J=7.8), 7.19(d, 2H, J=8.7), 7.15(d, 2H, J=7.8), 6.95(t , 1H, J=7.8), 6.82 (br s, 1H), 6.48 (br s, 1H), 5.49 (s, 1H), 3.56-3.46 (m, 4H), 2.34 (s, 3H), 1.67-1.52 (m, 6H); ESI-MS m / z 360 (MH + ).
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Property
Measurement
Unit
molecular weight
aaaaa
aaaaa
molecular weight
aaaaa
aaaaa
Login to View More
Abstract
This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and apharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and / or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and / or anxiety. This invention also provides a method of treating depression and / or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist.
Description
[0001] This application is a divisional application of Chinese patent application 02807754.7 filed on January 31, 2002 entitled "Use of GAL3 receptor antagonists in the treatment of depression and / or anxiety and compounds useful in such methods". Background of the invention [0002] Throughout this application, a number of publications are referenced, with author and year indicated in parentheses. Full citations for these references appear at the end of the specification. The entirety of these publications are incorporated by reference in this application to more fully illustrate the state of the art to which this invention pertains. [0003] Depression is the most common psychiatric disorder and to date is often underdiagnosed and undertreated, resulting in high morbidity and psychosocial impairment in patients. Depression is characterized primarily by sadness, apathy, loss of sensation, anhedonia (absence of pleasure), crying, agitation or dullness, feelings of guilt, and f...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More